Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2011 1
2012 1
2013 2
2014 5
2015 3
2016 1
2017 1
2018 1
2020 2
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Comparing the frequency of CD33(+) pSTAT3(+) myeloid-derived suppressor cells and IL-17(+) lymphocytes in patients with prostate cancer and benign prostatic hyperplasia.
Sanaei MJ, Taheri F, Heshmati M, Bashash D, Nazmabadi R, Mohammad-Alibeigi F, Nahid-Samiei M, Shirzad H, Bagheri N. Sanaei MJ, et al. Cell Biol Int. 2021 Oct;45(10):2086-2095. doi: 10.1002/cbin.11651. Epub 2021 Jun 29. Cell Biol Int. 2021. PMID: 34184811
Prostate cancer (PCa) is one of the most epidemic types of cancer in men. ...On the other hand, IL-17(+) helper T cells (Th17) induce MDSCs and chronic inflammation in TME by producing IL-17. This study demonstrated that the frequency of CD33(+) pSTAT3(+) MDSC and I …
Prostate cancer (PCa) is one of the most epidemic types of cancer in men. ...On the other hand, IL-17(+) helper T cells (Th17) induce …
Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage.
Di Meo S, Airoldi I, Sorrentino C, Zorzoli A, Esposito S, Di Carlo E. Di Meo S, et al. Clin Cancer Res. 2014 Feb 1;20(3):585-94. doi: 10.1158/1078-0432.CCR-13-2240. Epub 2013 Nov 25. Clin Cancer Res. 2014. PMID: 24277453
IL-30 regulation of hPCa cell viability and expression of selected gene clusters was tested by flow cytometry and PCR array. RESULTS: IL-30, absent in normal prostatic epithelia, was expressed by cancerous epithelia with Gleason 7% of 21.3% of prostate cancer stage …
IL-30 regulation of hPCa cell viability and expression of selected gene clusters was tested by flow cytometry and PCR array. RESULTS: IL-30, …
Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison.
Brusa D, Simone M, Gontero P, Spadi R, Racca P, Micari J, Degiuli M, Carletto S, Tizzani A, Matera L. Brusa D, et al. Int J Urol. 2013 Oct;20(10):971-8. doi: 10.1111/iju.12086. Epub 2013 Feb 20. Int J Urol. 2013. PMID: 23421558
This was not the case for CD14(-) HLA-DR(low) CD33(+) CD11b(+) cells. Furthermore, postsurgical normalization of CD14(+) HLA-DR(low) cells only occurred in prostate cancer patients. ...This observation supports the principle that the appropriate setting for prost …
This was not the case for CD14(-) HLA-DR(low) CD33(+) CD11b(+) cells. Furthermore, postsurgical normalization of CD14(+) HLA-DR(low) …
The application of prostate specific membrane antigen in CART-cell therapy for treatment of prostate carcinoma (Review).
Ullah K, Addai Peprah F, Yu F, Shi H. Ullah K, et al. Oncol Rep. 2018 Dec;40(6):3136-3143. doi: 10.3892/or.2018.6758. Epub 2018 Oct 1. Oncol Rep. 2018. PMID: 30542701 Review.
With respect to prostate cancer, prostatic acid phosphatase, prostate-specific antigen, prostate-specific membrane antigen (PSMA), prostate stem cell antigen, T-cell receptor gamma alternate reading frame protein, transient receptor potential-p8 …
With respect to prostate cancer, prostatic acid phosphatase, prostate-specific antigen, prostate-specific membra …
Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer.
Chi N, Tan Z, Ma K, Bao L, Yun Z. Chi N, et al. Int J Clin Exp Med. 2014 Oct 15;7(10):3181-92. eCollection 2014. Int J Clin Exp Med. 2014. PMID: 25419348 Free PMC article.
AIM: Myeloid-derived suppressor cells (MDSCs) are a population of cells which negatively regulate immune response during tumor progression. In this study, we assessed the accumulation of MDSCs (CD33(+)CD11b(+)HLA-DR(-)CD14(-)) in patients with prostate cancer and it …
AIM: Myeloid-derived suppressor cells (MDSCs) are a population of cells which negatively regulate immune response during tumor progression. …
Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase.
Lerman I, Garcia-Hernandez ML, Rangel-Moreno J, Chiriboga L, Pan C, Nastiuk KL, Krolewski JJ, Sen A, Hammes SR. Lerman I, et al. Mol Cancer Res. 2017 Sep;15(9):1138-1152. doi: 10.1158/1541-7786.MCR-17-0003. Epub 2017 May 16. Mol Cancer Res. 2017. PMID: 28512253 Free PMC article.
Indeed, it was determined that NE is expressed by infiltrating immune cells and is enzymatically active in prostate cancer xenografts and in prostate tumors of prostate-specific Pten-null mice. ...Mechanistically, NE activated MAPK signaling and induced MAPK- …
Indeed, it was determined that NE is expressed by infiltrating immune cells and is enzymatically active in prostate cancer xenografts …
Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS. Freedland SJ, et al. Prostate. 2003 Apr 1;55(1):71-80. doi: 10.1002/pros.10202. Prostate. 2003. PMID: 12640663
When CD10 expression was examined in a tissue microarray, CD10 expression was below the 25th percentile of matched normal prostate tissue in 68% of prostate cancers, below the median expression of matched normal prostate tissue in 86% of cancers, and complete …
When CD10 expression was examined in a tissue microarray, CD10 expression was below the 25th percentile of matched normal prostate ti …
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB, Wickstroem K, Hammer S, Bjerke RM, Zitzmann-Kolbe S, Ryan OB, Karlsson J, Scholz A, Hennekes H, Mumberg D, Cuthbertson AS. Hagemann UB, et al. Cancer Biother Radiopharm. 2020 Sep;35(7):497-510. doi: 10.1089/cbr.2020.3568. Epub 2020 Apr 7. Cancer Biother Radiopharm. 2020. PMID: 32255671 Free PMC article. Review.
To date, radium-223 ((223)Ra) is the only TAT approved for the treatment of patients with metastatic castration-resistant prostate cancer. Thorium-227 ((227)Th), the progenitor nuclide of (223)Ra, offers promise as a wider-ranging alternative due to the availability of eff …
To date, radium-223 ((223)Ra) is the only TAT approved for the treatment of patients with metastatic castration-resistant prostate ca …
Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes.
Gužvić M, Braun B, Ganzer R, Burger M, Nerlich M, Winkler S, Werner-Klein M, Czyż ZT, Polzer B, Klein CA. Gužvić M, et al. Cancer Res. 2014 Dec 15;74(24):7383-94. doi: 10.1158/0008-5472.CAN-14-0934. Epub 2014 Oct 15. Cancer Res. 2014. PMID: 25320011
Bone is the most frequent site of metastasis in prostate cancer and patients with bone metastases are deemed incurable. Targeting prostate cancer cells that disseminated to the bone marrow before surgery and before metastatic outgrowth may therefore prevent lethal m …
Bone is the most frequent site of metastasis in prostate cancer and patients with bone metastases are deemed incurable. Targeting …
Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
Li J, Lam M; Reproducibility Project: Cancer Biology. Li J, et al. Elife. 2015 Jul 31;4:e06434. doi: 10.7554/eLife.06434. Elife. 2015. PMID: 26231042 Free PMC article.
Liu and colleagues first demonstrated that miR-34a levels were reduced in CD44+ prostate cancer cells (Figure 1B). They then showed that xenograft tumors from cells expressing exogenous miR-34a were smaller in size than control tumors (Supplemental Figure 5C). Tumors with …
Liu and colleagues first demonstrated that miR-34a levels were reduced in CD44+ prostate cancer cells (Figure 1B). They then showed t …
19 results